This case study, developed by the Optimal CAB with support from CHAI, outlines the mobilization of community members in response to the WHO-issued advisory on the risks of neural tube defects (NTDs) for women using dolutegravir (DTG) in their HIV treatment, including reflections on the implications for access to optimal HIV treatment, choice, and equity.